POWER3 RECEIVES FDA GUIDANCE REGARDING NUROPRO

Power3 Medical Products announced that it met with the FDA on June 1 regarding its pre-investigational device exemption submission for the first in a series of its NuroPro blood tests for the early detection and differentiation of neuromuscular diseases, such as Amyotrophic Lateral Sclerosis and Parkinson's disease. In the meeting with the FDA, guidance was offered regarding requirements for study design, patient risk assessment and intended use.

()a href="http://biz.yahoo.com/prnews/050620/nym207.html?.v=14" target="_blank">Yahoo News